Literature DB >> 20804521

Idiopathic intracranial hypertension in the USA: the role of obesity in establishing prevalence and healthcare costs.

D Friesner1, R Rosenman, B M Lobb, E Tanne.   

Abstract

This study documents for the first time the extraordinary costs to take care of patients with a chronic, non-fatal, relatively rare disorder who have been incorrectly thought to have an insignificant and self-limiting illness. Idiopathic intracranial hypertension (IIH) occurs worldwide and in all racial groups and is found predominantly in obese women (∼ 90%) of childbearing age. Although the incidence of IIH is increasing as a result of the rapid increase in obesity, the disorder in general receives little recognition, and no recognition of the extensive burden of healthcare costs placed on patients, their families and society. We established for the first time both the prevalence of IIH in the USA and the direct and indirect costs of IIH using a prevalence-based model. IIH patients had an exceptionally high hospital admission rate of 38% (in 2007), a partial reflection of unsatisfactory treatment options. The total hospital costs per IIH admission in 2007 were four times greater than for a population-based per person admission. Total economic costs of IIH patients exceeded $444 million. Programmes designed to reduce obesity prior to and after diagnosis and better therapeutics will have a tremendous economic impact.
© 2010 The Authors. obesity reviews © 2010 International Association for the Study of Obesity.

Entities:  

Mesh:

Year:  2010        PMID: 20804521     DOI: 10.1111/j.1467-789X.2010.00799.x

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  41 in total

1.  MRI evidence of impaired CSF homeostasis in obesity-associated idiopathic intracranial hypertension.

Authors:  N Alperin; S Ranganathan; A M Bagci; D J Adams; B Ertl-Wagner; E Saraf-Lavi; E M Sklar; B L Lam
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-05       Impact factor: 3.825

2.  Idiopathic intracranial hypertension is not benign: a long-term outcome study.

Authors:  Hanne M Yri; Marianne Wegener; Birgit Sander; Rigmor Jensen
Journal:  J Neurol       Date:  2011-10-19       Impact factor: 4.849

Review 3.  Current concepts and strategies in the diagnosis and management of idiopathic intracranial hypertension in adults.

Authors:  Jane W Chan
Journal:  J Neurol       Date:  2017-01-31       Impact factor: 4.849

4.  Acetazolamide for pseudotumor cerebri: evidence from the NORDIC trial.

Authors:  Jonathan C Horton
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

Review 5.  Cerebral venous sinus stenting for pseudotumor cerebri: A review.

Authors:  Sivashakthi Kanagalingam; Prem S Subramanian
Journal:  Saudi J Ophthalmol       Date:  2014-09-27

6.  Differing presenting features of idiopathic intracranial hypertension in the UK and US.

Authors:  R J Blanch; C Vasseneix; A Liczkowski; A Yiangou; A Aojula; J A Micieli; S P Mollan; N J Newman; V Biousse; B B Bruce; A Sinclair
Journal:  Eye (Lond)       Date:  2019-02-19       Impact factor: 3.775

Review 7.  Update on the pathophysiology and management of idiopathic intracranial hypertension.

Authors:  Valérie Biousse; Beau B Bruce; Nancy J Newman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-03-15       Impact factor: 10.154

8.  Transverse sinus stenting for pseudotumor cerebri: a cost comparison with CSF shunting.

Authors:  R M Ahmed; F Zmudzki; G D Parker; B K Owler; G M Halmagyi
Journal:  AJNR Am J Neuroradiol       Date:  2013-11-28       Impact factor: 3.825

9.  An institutional review of hospital resource utilization and patient radiation exposure in shunted idiopathic intracranial hypertension.

Authors:  Tyler Cho; Daniel Kreatsoulas; Joel Fritz; John M McGregor; Douglas A Hardesty
Journal:  Neurosurg Rev       Date:  2021-02-21       Impact factor: 3.042

10.  Re-evaluating the Incidence of Idiopathic Intracranial Hypertension in an Era of Increasing Obesity.

Authors:  Khin P Kilgore; Michael S Lee; Jacqueline A Leavitt; Bahram Mokri; David O Hodge; Ryan D Frank; John J Chen
Journal:  Ophthalmology       Date:  2017-02-07       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.